Dr. Howard Smith Oncall

  Vidcast:  https://youtu.be/OnuvfszO7kE   One hallmark of successful cancer immunotherapy is the deployment of checkpoint inhibitors, antibodies against the PD-1 receptors on lymphocytes that prevent them from killing cancer cells.  These must be repeatedly infused intravenously to trigger the army of killer white cells.   A just published study from Ohio State shows that even more powerful checkpoint antibodies may be synthesized using an immunogenic peptide PD1-Vaxx.  The vaccine prompts production of multiple antibodies to multiple sites on the PD-1 receptor.   This vaccine shows significant anti-cancer activity in a mouse human colon cancer model.  It remains to future studies to test it on humans.  This vaccine could also induce anti-cancer surveillance preventing emergence of tumors.   https://www.tandfonline.com/doi/full/10.1080/2162402X.2020.1818437   #cancer #vaccine #checkpoint #pd1